Journal of Psychopharmacology
March 1, 2006
Liesbeth Reneman, Maartje M. L. de Win, Wim van den Brink et al.
85 citations
Users of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) may be at risk of developing MDMA-induced injury to the serotonin (5-HT) system. Previously, there were no methods available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivoneuroimaging tools have begun to provide insights into the effects of ecstasy on the human brain....
Synapse
September 5, 2002
Liesbeth Reneman, Jan Booij, Jan B. A. Habraken et al.
33 citations
Abstract Recent [ 123 I]β‐CIT single‐photon emission computed tomography (SPECT) studies revealed decreased serotonin transporters (SERT) density in the brain of humans with a history of MDMA (“Ecstasy”) use. However, [ 123 I]β‐CIT SPECT has until now not been validated as a method for detecting such serotonergic lesions. Therefore, the present study was undertaken. Following baseline [ 123...
Human Psychopharmacology Clinical and Experimental
December 1, 2001
Liesbeth Reneman, Jan Booij, Charles B.l.m. Majoie et al.
50 citations
Abstract Human users of 3,4‐methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) users may be at risk of developing MDMA‐induced neuronal injury. Previously, no methods were available for directly evaluating the neurotoxic effects of MDMA in the living human brain. However, development of in vivo neuroimaging tools has begun to provide insights into the effects of MDMA in the human brain. In this...
Archives of General Psychiatry
October 1, 2001
Liesbeth Reneman, Jules Lavalaye, Ben Schmand et al.
192 citations
The present study suggests that, while the neurotoxic effects of MDMA on 5-HT neurons in the human cortex may be reversible, the effects of MDMA on memory function may be long-lasting.